Pharmaceuticals, Biotechnology and Life Sciences
Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor…
TORONTO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/FSDDF?src=hash” target=”_blank”gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today the appointment…
SAGINAW, Mich.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/NPN?src=hash" target="_blank"gt;#NPNlt;/agt;–Graminex® L.L.C., producer of Graminex® Non-Solvent Flower Pollen Extracts™, receives Health Canada Approval under the Natural…
WALTHAM, Mass.–(BUSINESS WIRE)–Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced that investigators will…
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that…
Belgian Oxurion has enrolled 70 patients for Phase 2 testing of its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).
IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc., the largest member-driven health care performance improvement company in the country, today announced the recognition of…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its…
Sandoz is resubmitting its Biologics License Application for a proposed biosimilar pegfilgrastim to the US FDA